Navigation Links
Sanofi Announces Positive Phase 3 Results for Investigational New Insulin U300
Date:6/22/2013

PARIS, June 22, 2013 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) announced today that the first Phase 3 study results (EDITION I) for its investigational new insulin U300 showed equivalent blood sugar control with fewer night-time low blood sugar events compared to Lantus® (insulin glargine [rDNA origin] injection). The company also announced topline results of a second Phase 3 study (EDITION II) for new insulin U300 that also demonstrated similar blood sugar reduction while fewer patients experienced night-time low blood sugar events compared with Lantus®.

(Logo: http://photos.prnewswire.com/prnh/20110624/NY25833LOGO )

These results are from EDITION I and EDITION II respectively and are part of the EDITION Phase 3 clinical program evaluating the efficacy and safety of the investigational new insulin U300 in people with diabetes.  The EDITION I data was presented at the 73rd Scientific Sessions of the American Diabetes Association.

"To properly manage diabetes, it is critical to control blood sugar and to reduce the risk of low blood sugar events, especially at night," said Matthew Riddle, Professor of Medicine, Division of Endocrinology/Diabetes/Clinical Nutrition, Oregon Health and Science University, U.S., and Principal Investigator for the EDITION I study. "I am encouraged by these findings, and look forward to the results of the full Phase 3 EDITION program, which will further reveal how this investigational basal insulin may help people living with diabetes."

EDITION IAs the first study of the EDITION Phase 3 program, EDITION I evaluated the efficacy and safety of investigational new insulin U300, vs. Lantus® in people with type 2 diabetes using basal pl
'/>"/>

SOURCE Sanofi
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Sanofi Announces Positive Phase 3 Data for Once-Daily Lixisenatide for Type 2 Diabetes
2. Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine
3. Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis
4. The Zacks Analyst Blog Highlights: Genomic Health, Sanofi, Regeneron Pharmaceuticals, Amgen and Isis Pharmaceuticals
5. Sanofi and Regeneron Announce Patient Enrollment in Two Phase 3 Trials with Sarilumab in Rheumatoid Arthritis (RA)
6. Tolero Pharmaceuticals announces Worldwide Agreement with Sanofi for the In-license of Alvocidib (Flavopiridol)
7. NextBio Announces Translational Medicine Partnership with Sanofi
8. Hemodialysis Patient Share for Sanofis Ferrlecit Increased Significantly in the First Quarter of 2013 Compared to the Previous Quarter
9. Sanofi US Offers a New Way to Say "Thank You" and Recognize the Unsung Heroes of Severe Allergy Awareness
10. Sanofi and Regeneron Report Positive Proof-of-Concept Data for Dupilumab, an IL-4R alpha Antibody, in Atopic Dermatitis
11. Sanofi New Drug Application for Lixisenatide Accepted for Review by FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/28/2014)... , Nov. 28, 2014 The market ... to reach 7.9 billion dollars in 2014 according to ... of existing equipment and growing incidence of disease are ... Information,s X-Ray and Digital X-Ray: World Market Analysis ... Digital X-Ray: World Market Analysis can be obtained ...
(Date:11/28/2014)... 28, 2014  (Booth #7309, North Hall) — ... newest product, DCMSYS Interface WebBridge, at the 100th annual ... McCormick Place, Chicago, Illinois . ... Designed for medical facilities of any size, WebBridge ... upload any non-standard data (e.g. JPEG, TFF, PDF, TXT, ...
(Date:11/28/2014)... DONGGUAN, China , Nov. 28, 2014 ... 300328, "Eontec") announced that its biodegradable magnesium alloy bone ... an innovative medical apparatus and instrument and ... Eontec said in an interview with Science and ... Tao , that the company chairman and founder, Professor ...
Breaking Medicine Technology:Kalorama: X-Ray and Digital X-Ray Market Nears 8 Billion This Year 2Kalorama: X-Ray and Digital X-Ray Market Nears 8 Billion This Year 3Dicom Systems Announces WebBridge Interface at RSNA 2014 2Chinese magnesium alloy manufacturer Eontec expects to have its medical magnesium alloy available for clinical trial in 2015 2Chinese magnesium alloy manufacturer Eontec expects to have its medical magnesium alloy available for clinical trial in 2015 3Chinese magnesium alloy manufacturer Eontec expects to have its medical magnesium alloy available for clinical trial in 2015 4
... GlySure Limited, developer of in-hospital continuous ... its $10.9 million Series C financing round. GlySure will ... approval in the United States and Europe. ... well as existing investors Amadeus Capital Partners, Chester Investments ...
... -- Global Pharm Holdings Group, Inc. (OTCBB: GPHG) ... integrated pharmaceutical company engaged in the distribution of ... herbal cultivation and sales in China through its ... today announced the appointment of Mr. Kwong Chi ...
Cached Medicine Technology:GlySure Secures $10.9 Million in Series C Financing Round 2Global Pharm Holdings Group, Inc. Strengthens its Board by Adding a Non-Executive Director 2Global Pharm Holdings Group, Inc. Strengthens its Board by Adding a Non-Executive Director 3
(Date:11/28/2014)... Now that the holiday season is here, ... nation's leading cash-for-junk-cars companies, is improving their cash offers ... competitive and help bring a little bit more joy ... year. , Along with purchasing expensive gifts for family ... deal with large travel expenses during the holiday season. ...
(Date:11/28/2014)... November 28, 2014 Novatus, a ... its Release v5.1 which provides customers with greater ... options. , “As we continue to evolve ... provide more functionality and improved performance in response ... CEO for Novatus. “With the enhancements that we ...
(Date:11/28/2014)... Wisconsin (PRWEB) November 28, 2014 Dr. ... plastic surgeons , announced the expansion of Quintessa Aesthetic ... center will be located at W307 N1497 Golf Road ... , According to Dr. Campbell, the new Delafield location ... procedures for patients, including: Botox, filler injectables ...
(Date:11/28/2014)... Texas (PRWEB) November 28, 2014 Dr. Paul Vitenas, ... will hold a Glitter & Glow Holiday Event for those in ... treatments offered at his practice. Glitter & Glow will take place ... Dr. Vitenas’ new location in the heart of Houston at 4208 ... of holidays and hope that you will come and celebrate the ...
(Date:11/28/2014)... Written and narrated by award winning author ... “The Happiest Man In the World: Life Lessons From ... and why Project C.U.R.E. came to be. , Raised in ... the Reverend Richard W. Jackson, Dr. Jackson exceeded his goal ... realized that he wasn’t happy. Prompted by this realization, James ...
Breaking Medicine News(10 mins):Health News:Rusty's Auto Salvage Increasing Their Cash Offers to Help Drivers Save Throughout the Busy Holiday Season 2Health News:Novatus Releases v5.1 with New Advanced Reporting Capabilities 2Health News:Dr. Andrew Campbell to Expand Quintessa Aesthetic Center into Delafield 2Health News:Cosmetic Surgeon Dr. Paul Vitenas to Host Glitter & Glow Holiday Event 2Health News:Cosmetic Surgeon Dr. Paul Vitenas to Host Glitter & Glow Holiday Event 3Health News:Thanksgiving Weekend Audiobook Treat! “The Happiest Man In the World: Life Lessons From a Cultural Economist” by Dr. James W. Jackson 2
... Christmas Programs and Next Year,s Services , ... in Chicago is facing a grave financial shortfall which will ... pace of donations increases this Christmas season according to its ... , "The economic downturn has attacked us ...
... of millions of people, mainly in developing countries, are ... Organization. , More than 12 million people in ... spread by the bite of infected sand flies. Nearly ... people die from the disease annually. , Researchers ...
... high-energy diet pill really save your job? It seems that ... and other retailers are seeing a significant drop in sales ... is reporting dramatically increased sales of Zantrex-3 (R), their ... (Photo: http://www.newscom.com/cgi-bin/prnh/20081216/LA52707 ) , , ...
... in mucus could fight deadly,bacteria in lungs , , TUESDAY, ... that stain the mucus in the lungs of cystic ... infections, researchers say. , The pigments may enable infectious ... communities, according to a Massachusetts Institute of Technology (MIT) ...
... that they know. Or maybe not. A new study published in Human ... human genome must pay attention to ancestry when analyzing and interpreting their ... ... someone where their ancestors were from and odds are that they know. ...
... Health (NIH) has awarded nearly $3 million to support Rush ... the health outcomes and health care cost savings for very ... , The grant will enable researchers at Rush to ... 600 very low birth weight infants born to racially and ...
Cached Medicine News:Health News:Salvation Army Services Threatened by Pace of Donations 2Health News:UIC researchers hunting drugs for devastating parasitic disease 2Health News:Sales of Energy-Boosting Diet Pills Skyrocket as the Economy Falters 2Health News:Scientists Spot Key to Cystic Fibrosis Infections 2Health News:Genome-wide Association Studies Must Account for Ancestry 2Health News:Genome-wide Association Studies Must Account for Ancestry 3Health News:Study examines how breastfeeding impacts cost of care for very low birth weight infants 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: